What To Expect From The Report
The 2022 ESMO Annual Meeting is over, but the connections, data, and information shared at the conference will stay with us. Our team of analysts have carefully screened all the ESMO 2022 abstracts and identified 45 (41 clinical, 4 preclinical) abstracts relating to ADC drugs and trials, and added them to the Beacon ADC database.
This report encompasses a detailed analysis of the 45 abstracts in the ADC space, including; clinical status and therapeutic class distribution, payload distribution, and trials by disease indication and phase.
You will also find a full summary of all 45 ADC abstracts ordered by clinical data of; approved ADCs, investigational ADCs, approved non-traditional ADCs, investigational non-traditional ADCs, and trial outline abstracts. The abstract summaries include the name and link to the drug (on Beacon), trial sponsor, abstract ID, phase, trial ID, disease indication, efficacy, safety, and description/dosing.
Find out more
The data from this post-conference report is available on the Beacon ADC platform.
Speak with our expert Team
Our dedicated team is on hand to showcase how Beacon can help you find the answers to your ADC questions.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements.